Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine Cagrilintide Simon's Compounding Cagrilintide, an amylin analog, enhances the weight loss effects of semaglutide or tirzepatide by slowing gastric emptying, suppressing glucagon, and reducing appetite. It works synergistically with Tirzepatide, a dual GIP GLP 1 receptor co agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction Cardiovascular Diabetology Springer Nature Link Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema in Adults with Overweight or Obesity: A Bayesian Network Meta Analysis Journal of Clinical Question CagriSema in Adults With or Without Diabetes REDEFINE 1 & 2 Cagrilintide 2.4 mg + Semaglutide 2.4 mg once weekly 20.4% weight loss (non diabetic) & 13.7% (T2D)